Table 3 |
|||
| Multivariate analysis for overall survival | |||
| Hazard Ratio | p | 95% C.I. | |
| WHO type (t-AML vs t-MDS) | 3.49 | 0.03 | 1.17-10.46 |
| Karyotype (aberrant versus normal) | 2.2 | 0.015 | 0.75-6.58 |
| Front-line AZA (no vs yes) | 3.45 | 0.08 | 0.87-13.62 |
Fianchi et al. Journal of Hematology & Oncology 2012 5:44 doi:10.1186/1756-8722-5-44
